West's SmartDose® Drug Delivery Technology Platform Selected by Amgen for Pushtronex™ System

EXTON, Pa., July 11, 2016 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the U.S. Food and Drug Administration (FDA) has approved the first combination product that incorporates its SmartDose® technology for use in the United States. Amgen announced FDA approval for a single, monthly 420 mg dose delivery option for Repatha® (evolocumab), utilizing the SmartDose technology, on July 11, 2016 (see release: http://www.amgen.com/media/).

"West is very pleased that Amgen has selected the SmartDose technology platform for the new monthly single dose administration option of Repatha," said Eric M. Green, President and CEO, West. "The combination of Amgen's innovative treatment with West's patient-focused technology platform is an example of how West closely collaborates with our pharmaceutical and biotechnology partners to deliver advanced, integrated solutions for drug delivery and containment."

West's SmartDose technology platform allows patients to self-administer medication in accordance with their prescribed treatment. West developed the SmartDose technology platform with extensive human factors testing and analysis to understand the interaction between the patient and the delivery system. The SmartDose technology platform adheres to the patient's body, usually on the abdomen, so patients can be hands free during administration. The SmartDose technology platform is an integrated solution of delivery and containment featuring a silicone-free Daikyo Crystal Zenith® cartridge and a Flurotec® coated piston containment system.

For more information about the SmartDose technology platform, or any of West's technologies for integrated drug delivery, visit www.smartdose.com or www.westpharma.com.

Certain forward-looking statements are included in this release. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that West's SmartDose technology platform will achieve any level of commercial success. These forward-looking statements involve a number of risks and uncertainties. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2015.

About West
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2015 sales of $1.4 billion reflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.

About Daikyo Seiko, Ltd.

Daikyo Seiko, Ltd. is a leading manufacturer of high-quality injectable packaging components that include: Daikyo Flurotec® film laminated elastomeric closures and Crystal Zenith® cyclic olefin polymer containment and delivery systems. Since the 1970s, Daikyo and West Pharmaceutical Services, Inc. have partnered to provide the pharmaceutical industry with a comprehensive portfolio of products for injectable drugs and healthcare products.

Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

West and the diamond logo and By your side for a healthier world™ and Flurotec are registered trademarks or trademarks of West Pharmaceutical Services, Inc.

SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc. West seeks partners for its SmartDose drug delivery technology platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.

Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd. Crystal Zenith and Flurotec technologies are licensed from Daikyo Seiko, Ltd.

Repatha® and Pushtronex™ are registered trademarks of Amgen Inc.

Media Contact 
Emily Denney 
Global Communications 
West Pharmaceutical Services 
+1-610-594-3035 
[email protected]

SOURCE West Pharmaceutical Services, Inc.

Related Links

http://www.westpharma.com